Can cyclodextrin suppositories be stored at 45 degrees Fahrenheit?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Storage of Cyclodextrin Suppositories at 45°F

Cyclodextrin suppositories should not be stored at 45°F (7°C) as this temperature is too cold and falls outside the recommended storage range for most pharmaceutical products. Based on available guidelines, most medications should be stored either at room temperature (20-25°C/68-77°F) or refrigerated at 2-8°C (35-46°F) 1.

Optimal Storage Conditions for Cyclodextrin Formulations

Temperature Considerations

  • Cyclodextrin complexes are most stable when stored at specific temperature ranges:
    • For refrigerated storage: 4°C (39°F) is recommended 1
    • For frozen storage: -20°C (not 45°F) is recommended for long-term stability 1
    • Room temperature storage may be acceptable for short periods but varies by specific formulation

Evidence-Based Storage Guidelines

  • According to pharmaceutical storage guidelines, 45°F (7°C) falls between refrigeration (35-46°F/2-8°C) and room temperature, which is not an optimal storage condition 1
  • Storing medications at temperatures outside recommended ranges can adversely affect potency 1
  • Cyclodextrin complexes prepared via freeze-drying have demonstrated stability for at least 6 months when stored at 4°C (39°F), not at 7°C (45°F) 2

Impact of Improper Storage on Cyclodextrin Formulations

Stability Concerns

  • Temperature fluctuations can affect the inclusion complex stability between cyclodextrins and active pharmaceutical ingredients
  • Research shows that hydroxypropyl-beta-cyclodextrin formulations maintain better chemical stability when stored at 6°C rather than at higher temperatures 3
  • Storing at 45°F may lead to:
    • Reduced stability of the cyclodextrin-drug complex
    • Potential precipitation of the active ingredient
    • Compromised therapeutic efficacy

Formulation-Specific Considerations

  • Different cyclodextrin derivatives (methylated, hydroxypropyl, sulfobutyl-ether) have varying temperature sensitivities 2
  • The specific drug complexed with cyclodextrin affects optimal storage conditions
  • Some cyclodextrin formulations (like paclitaxel/RAME-beta-CD) show highest stability at specific temperature ranges that don't include 45°F 2

Proper Storage Protocol for Cyclodextrin Suppositories

Recommended Approach

  1. Store cyclodextrin suppositories at 4°C (39°F) in a dedicated pharmaceutical refrigerator
  2. Avoid temperature fluctuations that could destabilize the formulation
  3. Keep away from freezing temperatures unless specifically indicated by manufacturer
  4. Follow manufacturer's specific storage instructions, which typically recommend either refrigeration (2-8°C) or room temperature storage (20-25°C)

Common Pitfalls to Avoid

  • Storing suppositories in household refrigerators with variable temperature zones
  • Placing medications near refrigerator cooling elements where freezing may occur
  • Assuming all cyclodextrin formulations have identical storage requirements
  • Neglecting to check manufacturer-specific storage instructions

In conclusion, while 45°F (7°C) is close to refrigeration temperature, it is not an optimal storage condition for cyclodextrin suppositories. For maximum stability and therapeutic efficacy, these formulations should be stored at the manufacturer-recommended temperature, which is typically either refrigerated at 4°C (39°F) or at controlled room temperature.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Paclitaxel/beta-cyclodextrin complexes for hyperthermic peritoneal perfusion - formulation and stability.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2007

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.